Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication Solid tumors NSCLC Roche Relapsed or refractory multiple myeloma (MM) or r/r B-cell NHL Phase/study # of patients Phase I N=540 " Phase la: Dose escalation and expansion of tiragolumab ■ Phase Ib: Dose escalation and expansion of tiragolumab in combination with Tecentriq and/or other anti-cancer therapies Phase II CITYSCAPE N=135 ARM A: Tecentriq plus tiragolumab ARM B: Tecentriq monotherapy Phase I N=52 Phase la: Tiragolumab monotherapy Phase Ib: Tiragolumab plus daratumumab (r/r MM) or rituximab (r/r NHL) " Design Primary endpoint Status CT Identifier Safety, tolerability, PK variability and preliminary efficacy " FPI Q2 2016 Data presented at AACR 2020 NCT02794571 Overall response rate and progression-free survival FPI Q3 2018 Recruitment completed Q2 2019 Data presented at ASCO 2020 and WCLC and ESMO IO 2021 OBTD granted by FDA Q4 2020 Safety, tolerability, PK/PD and preliminary efficacy ■ FPI Q2 2019 NCT03563716 NCT04045028 BTD=Breakthrough therapy designation; MM-Multiple myeloma; NSCLC=Non-small cell lung cancer; r/r-Relapsed refractory; NHL-Non-Hodgkin's lymphoma; PK-Pharmacokinetics; PD-Pharmacodynamics; ASCO=American Society of Clinical Oncology; AACR-American Association for Cancer Research; WCLC=World Conference on Lung Cancer; ESMO IO-European Society for Medical Oncology - Immuno-Oncology 130 Oncology
View entire presentation